Skip to main content
Premium Trial:

Request an Annual Quote

Caris & Company Upgrades Affy Stock to 'Above Average;' Shares Up 6 Percent

NEW YORK (GenomeWeb News) — Shares in Affymetrix were trading up 6.2 percent at $28.31 this afternoon, and an investment bank upgraded the stock to ‘above average’ from ‘average.’
 
Caris & Company made the upgrade after Affy’s fourth-quarter earnings per share beat analysts’ expectations.
 
As GenomeWeb News reported this morning, Affymetrix said fourth-quarter revenues decreased 6.5 percent as R&D spending remained flat and profit plummeted 72 percent.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.